Restoring Earnings Power Through Portfolio Restructuring and a Shift to New Drugs
First written in FY2018. 3 of 8 entries say "Reframed", first in FY2019. Latest entry: FY2026.
Mochida Pharmaceutical moved to the "Worse" side of this theme in 2019.
0 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Because profit contributions from the growth businesses are expected from FY2028 onward, the policy is to support growth through the core business during the 25-27 Medium-Term Management Plan period.」
The Company continues to position profit contributions from the growth businesses as beginning from FY2028 onward and to support growth through the core business during the 25-27 period. - FY2026-H1RestatedAnnual report
「In fiscal 2025, we formulated the 25-27 Medium-Term Management Plan, positioned as "3 years of accelerating the growth strategy" toward achieving our desired position. Under this plan, we are focusing on the following key themes: "strengthening the earnings power of core businesses," "continued investment in growth businesses," and "strengthening the management foundation supporting growth."」
Under the 25-27 Medium-Term Management Plan, the Company continues to focus on strengthening the profitability of the core business, continuing investment in the growth businesses, and strengthening its management platform. - FY2025ReframedAnnual report
「Because profit contributions from the growth businesses are expected from FY2028 onward, growth will be supported by the core business during the 25-27 Medium-Term Management Plan period.」
The positioning has changed from continuing growth investment under the 22-24 Medium-Term Management Plan to a plan in which profit contributions from the growth businesses are expected from FY2028 onward and growth is supported by the core business during the 25-27 period. - FY2022SoftenedAnnual report
「The Group also expects earnings to deteriorate temporarily during the period of the 2022–2024 medium-term management plan, but will continue growth investment to achieve its desired future state.」
The description has changed from restoring profitability during the previous medium-term plan period to continuing growth investment while anticipating a temporary deterioration in profitability under the 22-24 Medium-Term Management Plan. - FY2021RestatedAnnual report
「Over the next 3 years, we will continue to actively invest in R&D and other areas, including in-licensing, while improving the quality and accelerating the pace of the portfolio restructuring, including the shift toward new drugs, and of each initiative that has been under way for some time.」
While deciding not to disclose numerical targets, the Company has indicated that it will continue investing in R&D, pursuing the shift toward new drugs, and improving the quality and speed of its initiatives. - FY2020ReframedAnnual report
「Although FY2020, the first year of the 20-22 Medium-Term Management Plan, will be affected by a drug price revision for the third consecutive year, the Company will continue to actively invest in R&D and other areas, including in-licensing, for the future. Accordingly, current profitability remains in the process of recovery, but the Company aims to restore profitability during the medium-term management plan period through the portfolio restructuring, including the shift toward new drugs, that has been under way for some time, and through the advancement of its initiatives.」
The plan has been updated from the 19-21 Medium-Term Management Plan to the 20-22 Medium-Term Management Plan, and the timing for restoring profitability is now described as during the plan period rather than in the final year. The policy of continuing the shift toward new drugs and investment in R&D has been maintained. - FY2019ReframedAnnual report
「During the 19-21 Medium-Term Management Plan period, profitability in FY2019, the first year, is expected to remain in the process of recovery because, in addition to a drug price revision accompanying the consumption tax increase, the portfolio restructuring that has been under way for some time, including the shift toward new drugs, is still midway, while the Company actively invests in R&D and other areas, including in-licensing, for the future. However, the Company aims to restore profitability in FY2021, the final year of the plan, and thereafter, as the initiatives undertaken to date progress.」
The plan has been updated from the 18-20 Medium-Term Management Plan to the 19-21 Medium-Term Management Plan, with FY2019 positioned as a year in the process of recovery and FY2021 onward as the target period for restoring profitability. - FY2018First statedAnnual report
「During the 18-20 Medium-Term Management Plan period, profitability is expected to decline to a reasonable extent from FY2018, which will be the bottom, because in addition to the drug price revision in FY2018, the portfolio restructuring that has been under way for some time, including the shift toward new drugs, is still in progress, while R&D expenses remain high as investment for the future. However, the Company aims to restore profitability in FY2020, the final year of the plan, and thereafter, as the initiatives undertaken to date progress.」
The Company has newly stated its outlook for restoring profitability from FY2020 onward, with portfolio restructuring including the shift toward new drugs progressing and FY2018 as the bottom.